Cyclacel Pharmaceuticals received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement of $2.5 million, reporting only $607,000 as of December 31, 2023, and subsequently $999,000 as of June 30, 2024, leading to potential delisting unless an appeal is made by August 29, 2024.